Flagged for Manual Review
Round 3 merged 11 different OpenAlex profiles by name match alone (unverified)
Metrics shown are from the primary verified profile.11 name-matched profiles were discovered and excluded from these metrics.
Jason Chen
VIC, Australia · RMSANZ Member (Ordinary Membership) · FAFRM
Institution(s): AU
MM 1 - Metropolitan(Postcode: 2600)
Clinical Expertise (self-reported)
Research Expertise (self-reported)
Source: RMSANZ Member Survey 2025 (Chapter 3)
Click a bar to filter publications by year
Do changed behaviors predict cognitive decline in a community sample?
National Institutes of Health · 2025(5R01AG057531-03)
Do changed behaviors predict cognitive decline in a community sample?
National Health and Medical Research Council · 2025(ID350833)
Do changed behaviors predict cognitive decline in a community sample?
National Institutes of Health · 2025(5R01AG057531\u201303)
Do changed behaviors predict cognitive decline in a community sample?
National Health and Medical Research Council · 2025(ID568969)
Do changed behaviors predict cognitive decline in a community sample?
National Health and Medical Research Council · 2025(APP1093083)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Medical Research Council · 2020(MR/L501542/1)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Medical Research Council · 2020(MC_UU_00015/7)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Medical Research Council · 2020(MR/N026004/1)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Instituto de Salud Carlos III · 2019(PI16/)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
National Institute of Neurological Disorders and Stroke · 2019(R01 NS078086)
A5107898567Learning and Individual Differences
2013 · 470 citations